Navigation Links
VIVUS to Present at Four Upcoming Healthcare Conferences
Date:9/1/2009

MOUNTAIN VIEW, Calif., Sept. 1 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, Chief Financial Officer, will present an overview of the company at four healthcare investment conferences during the month of September.

The conference presentation schedule is as follows:

        Rodman & Renshaw Annual Global Investment Conference
        September 10, 2009 at 10:50 a.m. ET
        The New York Palace Hotel, New York, NY

        Thomas Weisel Partners Healthcare Conference
        September 11, 2009 at 11:30 a.m. ET
        The Four Seasons Hotel, Boston, MA

        BioCentury's NewsMakers in the Biotech Industry Conference
        September 16, 2009 at 3:30 p.m. ET
        Millennium Broadway Hotel & Conference Center, New York, NY

        UBS Global Life Sciences Conference
        September 21, 2009 at 3:30 p.m. ET
        Grand Hyatt, New York, NY

A live audio webcast and 30-day archive of the presentations will be available on VIVUS' website at http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:
    Timothy E. Morris
    Chief Financial Officer
    VIVUS, Inc.
    +1-650-934-5200,

    Brian Korb
    Investor Relations
    The Trout Group,
    +1-646-378-2923

    Sheryl Seapy
    Media Relations
    Pure Communications, Inc.
    +1-949-608-0841


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. VIVUS to Present at the Needham and Company Life Sciences Conference
3. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
4. VIVUS Reports First Quarter 2009 Financial Results and Highlights
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
6. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
7. Masimo to Present at the Thomas Weisel Partners Healthcare Conference 2009
8. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
9. Beckman Coulter to Present at Upcoming Healthcare Conferences
10. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
11. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... , ... FireflySci Inc. is a go-getter type of company that continues to ... two main factors. The first is the amazing customer service that the FireflySci ... all around the world. , 2016 was a tremendous sales year for FFS and ...
(Date:1/19/2017)... , Jan. 18, 2017 BD (Becton, Dickinson and ... announced today that it will host a live webcast of its ... p.m. (ET). The webcast can be accessed from ... for replay through Tuesday, January 31, 2017. ... About BD BD is a ...
(Date:1/18/2017)... --  Parent Project Muscular Dystrophy (PPMD) , a nonprofit ... dystrophy (Duchenne) , today announced a $600,000 grant to ... (NJIT) and Talem Technologies (Talem) as part of the ... assist people living with Duchenne. PPMD is funding a ... computer, software, a force sensor and a motor – ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which creates medical technology ... a 510(k) to the FDA, requesting clearance of the MyoCycle Home and the ... technology. , The submission marks a major milestone for the technology startup. ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical device ... billion by 2021 from USD 5.31 billion in 2016, at a ... ... driven by technological advancements in medical devices, launch of a growing ... for wireless connectivity among healthcare providers, and increasing focus on physical ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition ... Service, Application Area, End User, And Region - Global Forecast to 2021", published ... in 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):